Ontario-based psychedelic company, Revive Therapeutics, has partnered with psychedelic pharmaceutical company, PharmaTher, to study the delivery of 3,4-methylenedioxymethamphetamine (MDMA) using PharmaTher’s microneedle patch technology.
Under the terms of the agreement, both companies will work on a product and clinical development plan to initiate regulatory discussions to use MDMA for various indications, such as depression, anxiety, abuse disorders, and post-traumatic stress disorder, and most importantly, as an alternative to existing oral treatments. PharmaTher has already completed the non-clinical research study for the MDMA microneedle patch and results are expected to be released by Q2 2023.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.